Takeaways Daga Ciwon Cutar Cutar Cutar
A kowace shekara, {ungiyar {asashen Harkokin Harkokin Ilmin {asashen Amirka (ASH) tana gudanar da taron da ke gabatar da sabon bincike a kan magunguna da sauran ci gaba. Magunguna da aka tattauna a wannan taron suna cikin dukkanin hanyoyi na ci gaba na asibiti. A wasu kalmomi, wasu daga cikinsu suna da magungunan yanzu, sunyi kokarin da gaskiya, sun riga sun yarda da amfani, wasu kuma suna da magunguna masu mahimmanci, ma'ana ba mu sani ba game da su duk da haka.
Yi rituximab, alal misali. A shekara ta 2016, Rituximab an dauke shi "magani ne" wanda aka yi amfani dashi tsawon shekaru don magance nau'o'in lymphoma marasa Hodgkin. Tsofaffi, ƙwararrun maganin har yanzu suna iya yin motsi a ɗaya daga cikin waɗannan taro, alal misali, lokacin da aka gano sabon amfani.
Wasu kwayoyi da aka tattauna a ASH sune kawai a mataki na farko na cigaba - wato, abubuwan da aka raba su sune mahimmanci. Sau da yawa, ana nazarin waɗannan nazarin "Nazarin karatun zamani". Farkon na na nufin gwaje-gwaje na asibitocin da ke gwada sabon magani ko magani a cikin ƙananan ƙungiyoyin mutane - don farko idan na gani idan yana aiki, don samun samin lafiya iyakar, da kuma gano sakamakon illa. Matsalar na farko na kama da tsaba: za ku iya samun kyauta mai cin nasara ko 'ya'yan itace wanda za ku iya nunawa a jihar gaskiya, amma zaka iya samun gazawar shuka ko shuka wanda ba ya da' ya'ya mai yawa.
Binciken kan DLBCL
Kaddamar da babban lymphoma B-cell, ko DLBCL, wani lymphoma mai sauri.
Yawan lymphoma ne mafi yawancin manya, kuma yana fitowa ne daga jinin B-lymphocytes-fararen jini wadanda ke haifar da cutar ta hanyar samar da kwayoyin cuta a cikin tsarin rigakafi. Mutane daban-daban suna da nau'o'in DLBCL kuma masu bincike suna binciken sababbin zabin ga marasa lafiya da DLBCL .
Rituximab Plus CHOP ko DA-EPOCH-Rituximab
Ɗaya daga cikin nazarin binciken na III ya kasance 524 marasa lafiya da aka yi rajista (262 a kowannensu sarkar) tsakanin Mayu 2005 da Mayu 2013. Wannan binciken ya gwada magani na R-CHOP da magani DA-EPOCH-R, karin magani-jiyya mai tsanani, a cikin fata na cigaba da rayuwa marasa lafiya da kwanan nan da aka bincikar asibiti II ko mafi girma DLBCL.
Mahalarta sun kasance akalla shekaru 18 da cutar HIV. Ya zuwa yanzu, gaba ɗaya, DA-EPOCH-R ya danganta da yawan haɗari da kuma sakamakon illa, kuma babu bambanci a tsakanin kungiyoyi a cikin sharudda amfanin ilimin likita. Duk da haka, masu binciken suna neman ganin wasu ƙungiyoyi masu zaman kansu na DLBCL kuma suna amfani da DA-EPOCH-R za a nuna su ga ƙungiyoyin rabawa. Binciken yana gudana.
Obinutuzumab Plus CHOP ko Rituximab Plus CHOP
Wannan wani binciken na zamani na III tare da mambobin 1,418 sun yi nazari akan inganci da aminci na obinutuzumab vs. rituximab da CHOP a cikin marasa lafiya tare da DLBCL. Mahalarta sun kasance shekarun 18 da suka wuce kuma ba a yalwata musu ba saboda DLBCL. Yawanci, babu wani bambanci tsakanin kungiyoyi biyu dangane da amfanin rayuwa, kuma an kara yawan abubuwan da suka faru a cikin marasa lafiya a cikin ƙananan marasa lafiya a cikin obinutuzumab-CHOP fiye da kungiyar rituximab-CHOP. Yawanci, yawan ƙwayar mace-mace ya fi girma kuma ya janye daga jiyya mafi mahimmanci a cikin hannu na obinutuzumab -CHOP.
Duk da haka, masu binciken suna shirin yin la'akari da raƙuman ƙungiyoyi tare da DLBCL don gwadawa da samun duk wani amfani ko hadarin da ba a nuna a cikin rukuni ba.
Lenalidomide a cikin marasa lafiya tare da Rushe DLBCL
Mutanen da ba su cancanci samun karfin jini ba ko kuma suna fuskantar komawa baya bayan da aka samu suturar ƙwayar jiki yana iya samun magani, don haka ɗayan ƙungiyar bincike sun kalli amfani da magani don tsawanta rayuwa a cikin wadannan marasa lafiya.
Sun gano cewa lenalidomide wakili ne dan takara mai dacewa tun lokacin da yake da kwayoyi ne na maganin, wanda yake aiki da DLBCL wanda za a iya dauka tsawon shekaru tare da bayanan da ya dace.
Binciken ya nuna cewa tsofaffin marasa lafiya da daban-daban na DLBCL sun amfana daga farfadowar maganin lenalidomide tare da inganta rayuwa. Maganar kulawa tana nufin maganin ciwon daji tare da magani, yawanci ana biyan zagaye na farko na magani.
Binciken a kan Lymphoma Follicular
Lymphoma mai laushi shine ƙwayar da ba shi da kyau-watau, lymphoma mai raguwa. Duk da yake obinutuzumab bai yi amfani da komai ba tukuna duk da haka a cikin binciken DLBCL da aka ambata a sama, wannan ba lamari ne ga obinutuzumab a cikin lymphoma ba.
Tsarin maganin Obinutuzumab yana cigaba da ci gaba-tsira da lafiya a cikin marasa lafiya tare da tsohuwar ƙwayoyin cuta Lymphoma
Gwajin GALLIUM wani binciken ne na kasa da kasa na duniya wanda ya kwatanta da inganci da aminci na rituximab ko obinutuzumab da chemotherapy wanda ya biyo baya a matsayin kulawa na farko ga marasa lafiyar Hodgkin Lymphoma.
A cikin marasa lafiya tare da lymphoma follicular wanda ba a yalwata ba, tsarin tsarin kula da ilimin chemotherapy da tsarin kulawa na obinutuzumab ya haifar da ingantacciyar mahimmanci a cikin rayuwa ba tare da ci gaba da cutar ba - cigaba da kashi 34 cikin hadarin ci gaban zumunta da tsarin rituximab. Obinutuzumab yana da matsayi mafi girma na wasu abubuwa masu ban sha'awa irin su halayen jigilar jini, ƙananan jini, da cututtuka. Masu bincike sun kaddamar da goyon baya bayanan bayanan da ake amfani da su a cikin marasa lafiya marasa lafiya wanda ba a haramta ba tare da maganin lymphoma follicular.
Bincike kan Hodgkin Lymphoma
Akwai manyan nau'o'i guda uku na lymphoma Hodgkin (HL) wanda za'a iya gano mutum. Lymphoma Hodgkin na tsohuwar ƙwayar tsohuwar maganganu ce da aka kwatanta da ƙungiyar huɗun iri guda ɗaya waɗanda suka hada da kashi 95 bisa dari na duk lokuta na HL a kasashe masu ci gaba.
Binciken Bincike ba tare da izini ba don ƙwayoyin gargajiya na Lymphoma
Lymphoma na Lodic na gargajiya yana da alaka da canji na kwayoyin da zai sa ya dace da sabon magungunan da ake kira 'yan kwantar da hankular rigakafi , bisa ga binciken da suka gabata. Saboda haka, wata ƙungiyar bincike a ASH ta dubi marasa lafiya 210 da aka magance su don maganin cutar ko kuma sun sake komawa HL don su ga yadda mai yin magunguna pembrolizumab zai yi.
Wasu kwayoyin cutar kanjamau suna samar da PD-L1 mai yawa, kuma wannan wani abu ne wanda ke taimaka musu su guje wa harin kai tsaye. Pembrolizumab zai taimaka wajen dakatar da hakan. PD-1 tare da pembrolizumab ya yi aiki a kungiyoyin marasa lafiya da HL waɗanda suka rigaya sun yi wa wasu ƙwayoyin maganin. Pembrolizumab yana da mahimmancin amsawa ko da a cikin wata cuta wadda ta dace da cutar shan magani. Ƙarin ƙarin, ciki har da tsawon lokacin da aka sake mayar da martani a taron.
Binciken kan cutar sankarar bargo
Matsalar tallafi ga marasa lafiya tare da AML - Eltrombopag
A cikin marasa lafiya masu fama da cutar sankarar rigakafi don mummunan cutar sankarar bargo (AML) , wani lokacin ma'adin yana ci gaba da ragewa bayan chemotherapy, kuma wannan zai haifar da ƙarin haɗari na zub da jini, da buƙatar ƙwayoyin platinis, kuma marasa lafiya zasu iya haifar da halayen rigakafi zuwa platelets, wanda duk suna hana ci gaba.
A shekara ta 2016 wata kungiya ta ruwaito ta amfani da eltrombopag, maganin da ke tasowa jiki don samar da takaddun shaida, a cikin tsofaffi wadanda ke yin magani ga AML.
Sakamakon sun kasance na farko-wannan lokaci ne na gudanar da binciken-amma suna da alama sun sami nasara ta hanyar samun mutane su dawo da sauri daga chemo don kada su buƙaci yawancin jini. Akwai damuwa cewa wani wakili irin su eltrombopag zai iya hanzarta ci gaba da cutar sankarar bargo, baya ga wadatar da ake samu tare da taimakawa ga magungunan kwalliya ta sake dawowa, duk da haka, a wannan binciken babu wata hujja game da wannan hadarin.
Rushewa ko Kwayar cututtuka na Lymphoblastic Acceptable Acne Lymphoblastic cutar (ALL)
Babu tsarin daidaitacce don sake komawa ALL. Inotuzumab ozogamicin ita ce farfadowa da aka tsara ta FDA ga marasa lafiya tare da sake yaduwa ko cutar kyakken cutar ta lymphoblastic mai tsanani (ALL). A cikin gwaji na asibiti, inotuzumab ozogamicin ya haifar da haɓaka mai girma a kan tsararraki na yaudara a cikin marasa lafiya tare da KATAN DUKIYA ga, ko ba amsawa ba, wasu hanyoyin kwantar da hankali.
Inotuzumab ozogamicin wani bincike ne da ake amfani da kwayar cutar kwayoyin cuta wanda aka hade da wani wakili wanda zai iya kashe kwayoyin cutar kanjamau. Lokacin da miyagun ƙwayoyi ya ɗauka zuwa tag da ake kira CD22 a kan kwayoyin cutar ciwon daji, shi ya shiga cikin tantanin halitta inda yake sa DNA ya karya, yana haifar da mutuwar cell.
Abin da Bincike ke Neman Kai
Duk da yake lokuta ana yin taro don samar da likitoci tare da bincike na baya-bayan nan, bayanin shine sau da yawa ga waɗanda aka bincikar da yanayin, da kuma abokansu. Lokacin da ka ziyarci likitanka ka tambayi abin da ke faruwa a sabon filin-kasancewa cikin sanannun zai iya taimaka maka ka ji more a kula da lafiyarka.
> Sources:
> 469 Phase III Nazarin Random na R-CHOP DA DA-EPOCH-R da Rubuce-rubucen Halitta na Ƙarƙashin Ƙarƙashin Ƙarƙashin B-Cell Lymphoma: CALGB / Alliance 50303
> 474 Lenalidomide Tsare-gyare Aiki Mai Girma Ya Kamata Sakamakon Survival a cikin Marasa lafiya tare da Ruwa Mai Girma B-Cell Lymphoma (rDLBCL) Wadanda basu da cancanta ga Tsuntsauran Tsuntsauran Tsuntsauran Abinci (ASCT): Sakamako na karshe na Ɗaukaka Maɗaukaki Phase II Trial
> 470 Obinutuzumab ko Rituximab Plus COP a marasa lafiya tare da Tsohon B-Cell Lymphoma: Sakamako na karshe daga Label Bugu da Ƙari, Sakamakon Farawa 3 Nazarin (GOYA)
> 1107 Pembrolizumab a Cikin Gudun Kasawa / Harkokin Kasuwanci na Labaran Lymphoma: Binciken Farko na Ƙarshe na Mataki na 2 na Jiha-087
> 447 A Single Arm, Shirin II Nazarin Eltrombopag don inganta farfadowa da ƙwanƙolin ƙwayoyin cuta a tsofaffiyar tsofaffi tare da cutar cutar sankarar myeloid mai tsanani.
> 6 Gidawar ci gaba da ci gaba da ci gaba da ci gaba da ci gaba ta Obinutuzumab (PFS) a cikin marasa lafiya tare da tsohuwar ƙwayoyin cuta Lymphoma: Sakamako na farko na Randomed Phase 3 GALLIUM Nazarin